vs
InterDigital, Inc.（IDCC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是InterDigital, Inc.的1.1倍（$219.9M vs $205.4M），InterDigital, Inc.净利率更高（36.7% vs -1.0%，领先37.7%），Orthofix Medical Inc.同比增速更快（2.0% vs -2.4%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -4.1%）
InterDigital, Inc.是一家美国科技研发企业，成立于1972年，于纳斯达克挂牌上市，为标普600指数成分股，面向全球市场为移动设备、通信网络及相关服务领域提供无线与视频技术解决方案，在相关技术研发领域拥有深厚积累。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
IDCC vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$205.4M
营收增速更快
OFIX
高出4.4%
-2.4%
净利率更高
IDCC
高出37.7%
-1.0%
两年增速更快
OFIX
近两年复合增速
-4.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.4M | $219.9M |
| 净利润 | $75.3M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 40.0% | 0.2% |
| 净利率 | 36.7% | -1.0% |
| 营收同比 | -2.4% | 2.0% |
| 净利润同比 | -34.8% | 92.4% |
| 每股收益（稀释后） | $2.14 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDCCOFIX
| Q1 26 | $205.4M | — | ||
| Q4 25 | $158.2M | $219.9M | ||
| Q3 25 | $164.7M | $205.6M | ||
| Q2 25 | $300.6M | $203.1M | ||
| Q1 25 | $210.5M | $193.6M | ||
| Q4 24 | $252.8M | $215.7M | ||
| Q3 24 | $128.7M | $196.6M | ||
| Q2 24 | $223.5M | $198.6M |
净利润IDCCOFIX
| Q1 26 | $75.3M | — | ||
| Q4 25 | $43.0M | $-2.2M | ||
| Q3 25 | $67.5M | $-22.8M | ||
| Q2 25 | $180.6M | $-14.1M | ||
| Q1 25 | $115.6M | $-53.1M | ||
| Q4 24 | $133.1M | $-29.1M | ||
| Q3 24 | $34.2M | $-27.4M | ||
| Q2 24 | $109.7M | $-33.4M |
毛利率IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率IDCCOFIX
| Q1 26 | 40.0% | — | ||
| Q4 25 | 30.2% | 0.2% | ||
| Q3 25 | 46.0% | -8.3% | ||
| Q2 25 | 68.3% | -7.9% | ||
| Q1 25 | 62.6% | -25.2% | ||
| Q4 24 | 64.3% | -5.3% | ||
| Q3 24 | 30.6% | -9.6% | ||
| Q2 24 | 59.9% | -12.5% |
净利率IDCCOFIX
| Q1 26 | 36.7% | — | ||
| Q4 25 | 27.2% | -1.0% | ||
| Q3 25 | 41.0% | -11.1% | ||
| Q2 25 | 60.1% | -6.9% | ||
| Q1 25 | 54.9% | -27.4% | ||
| Q4 24 | 52.7% | -13.5% | ||
| Q3 24 | 26.6% | -13.9% | ||
| Q2 24 | 49.1% | -16.8% |
每股收益（稀释后）IDCCOFIX
| Q1 26 | $2.14 | — | ||
| Q4 25 | $1.07 | $-0.05 | ||
| Q3 25 | $1.93 | $-0.57 | ||
| Q2 25 | $5.35 | $-0.36 | ||
| Q1 25 | $3.45 | $-1.35 | ||
| Q4 24 | $4.12 | $-0.76 | ||
| Q3 24 | $1.14 | $-0.71 | ||
| Q2 24 | $3.93 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $377.8M | — |
| 股东权益账面价值 | $1.1B | $450.0M |
| 总资产 | $2.1B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $82.0M | ||
| Q3 25 | $1.3B | $62.9M | ||
| Q2 25 | $937.0M | $65.6M | ||
| Q1 25 | $883.3M | $58.0M | ||
| Q4 24 | $958.2M | $83.2M | ||
| Q3 24 | $813.2M | $30.1M | ||
| Q2 24 | $760.3M | $26.4M |
总债务IDCCOFIX
| Q1 26 | $377.8M | — | ||
| Q4 25 | $16.3M | — | ||
| Q3 25 | $17.1M | $157.2M | ||
| Q2 25 | $16.6M | $157.0M | ||
| Q1 25 | $16.0M | $156.9M | ||
| Q4 24 | $15.4M | $157.0M | ||
| Q3 24 | $18.3M | $118.5M | ||
| Q2 24 | $17.7M | $118.0M |
股东权益IDCCOFIX
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $450.0M | ||
| Q3 25 | $1.1B | $442.5M | ||
| Q2 25 | $1.1B | $458.3M | ||
| Q1 25 | $936.9M | $458.3M | ||
| Q4 24 | $857.2M | $503.1M | ||
| Q3 24 | $722.5M | $525.9M | ||
| Q2 24 | $696.8M | $546.0M |
总资产IDCCOFIX
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $850.6M | ||
| Q3 25 | $2.1B | $832.6M | ||
| Q2 25 | $2.0B | $837.2M | ||
| Q1 25 | $1.9B | $823.1M | ||
| Q4 24 | $1.8B | $893.3M | ||
| Q3 24 | $1.7B | $867.9M | ||
| Q2 24 | $1.6B | $882.0M |
负债/权益比IDCCOFIX
| Q1 26 | 0.34× | — | ||
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | 0.36× | ||
| Q2 25 | 0.02× | 0.34× | ||
| Q1 25 | 0.02× | 0.34× | ||
| Q4 24 | 0.02× | 0.31× | ||
| Q3 24 | 0.03× | 0.23× | ||
| Q2 24 | 0.03× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $544.5M | $27.7M | ||
| Q3 25 | $395.9M | $12.4M | ||
| Q2 25 | $105.1M | $11.6M | ||
| Q1 25 | $-20.0M | $-18.4M | ||
| Q4 24 | $271.5M | $23.7M | ||
| Q3 24 | $77.6M | $11.7M | ||
| Q2 24 | $-48.9M | $9.0M |
自由现金流IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $528.6M | $16.8M | ||
| Q3 25 | $395.3M | $2.5M | ||
| Q2 25 | $104.5M | $4.5M | ||
| Q1 25 | $-34.5M | $-25.1M | ||
| Q4 24 | $265.7M | $15.2M | ||
| Q3 24 | $76.7M | $6.3M | ||
| Q2 24 | $-49.5M | $-360.0K |
自由现金流率IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 334.0% | 7.6% | ||
| Q3 25 | 240.1% | 1.2% | ||
| Q2 25 | 34.8% | 2.2% | ||
| Q1 25 | -16.4% | -13.0% | ||
| Q4 24 | 105.1% | 7.0% | ||
| Q3 24 | 59.6% | 3.2% | ||
| Q2 24 | -22.1% | -0.2% |
资本支出强度IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | 4.9% | ||
| Q3 25 | 0.4% | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | 6.9% | 3.5% | ||
| Q4 24 | 2.3% | 4.0% | ||
| Q3 24 | 0.7% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% |
现金转化率IDCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 12.67× | — | ||
| Q3 25 | 5.87× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | -0.17× | — | ||
| Q4 24 | 2.04× | — | ||
| Q3 24 | 2.27× | — | ||
| Q2 24 | -0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDCC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
